FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061000716> ?p ?o ?g. }

• W2061000716 endingPage "348" @default.
• W2061000716 startingPage "342" @default.
• W2061000716 abstract "The efficacy and toxicity of a combination of fludarabine and cyclophosphamide (FC) was evaluated in patients with B‐cell chronic lymphocytic leukaemia (CLL). Between April 1997 and July 1998, 36 patients with CLL (median age 59 years) received a regimen that consisted of fludarabine 30 mg/m 2 in a 30‐min IV infusion, d 1–3, and cyclophosphamide 250 mg/m 2 in a 30‐min IV infusion on d 1–3. Cycles were repeated every 28 d. Twenty‐one patients had received between one and three different treatment regimens prior to the study, while 15 patients had received no prior therapy. The median Eastern Cooperative Oncology Group performance score was 1. One patient was at Binet stage A, 18 were stage B and 17 patients were stage C. Objective responses, assessed according to the revised guidelines of the National Cancer Institute‐sponsored Working Group, were recorded in 29 out of 32 assessable patients (90·6%). Twenty‐four partial remissions and five complete remissions were observed. Two patients showed no change and one patient showed disease progression. At February 2000, three of the responders had relapsed. Severe neutropenia, anaemia and thrombocytopenia (Common Toxicity Criteria grade 3 and 4) were observed in 25, six and six patients (69·4%, 16·7% and 16·7%) respectively. Other side‐effects were uncommon. No treatment‐related deaths and no grade 3 or 4 infections occurred. We conclude that the combination of fludarabine and cyclophosphamide showed significant activity in patients with CLL. Myelosuppression was the major side‐effect. These results warrant further study on the FC combination in randomized trials." @default.
• W2061000716 created "2016-06-24" @default.
• W2061000716 creator A5003574683 @default.
• W2061000716 creator A5005594026 @default.
• W2061000716 creator A5010456669 @default.
• W2061000716 creator A5013939045 @default.
• W2061000716 creator A5019048597 @default.
• W2061000716 creator A5020907777 @default.
• W2061000716 creator A5021332351 @default.
• W2061000716 creator A5025166897 @default.
• W2061000716 creator A5029984844 @default.
• W2061000716 creator A5031856721 @default.
• W2061000716 creator A5033935778 @default.
• W2061000716 creator A5047187056 @default.
• W2061000716 creator A5067184222 @default.
• W2061000716 creator A5073667628 @default.
• W2061000716 creator A5075280681 @default.
• W2061000716 creator A5076077834 @default.
• W2061000716 creator A5077198246 @default.
• W2061000716 creator A5078557608 @default.
• W2061000716 creator A5084862920 @default.
• W2061000716 creator A5089395073 @default.
• W2061000716 date "2001-08-01" @default.
• W2061000716 modified "2023-10-16" @default.
• W2061000716 title "Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group" @default.
• W2061000716 cites W1494274243 @default.
• W2061000716 cites W1965851569 @default.
• W2061000716 cites W2066335501 @default.
• W2061000716 cites W2070193300 @default.
• W2061000716 cites W2323490326 @default.
• W2061000716 cites W2326175431 @default.
• W2061000716 cites W4235838915 @default.
• W2061000716 cites W4237443037 @default.
• W2061000716 cites W60865865 @default.
• W2061000716 doi "https://doi.org/10.1046/j.1365-2141.2001.02959.x" @default.
• W2061000716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11529853" @default.
• W2061000716 hasPublicationYear "2001" @default.
• W2061000716 type Work @default.
• W2061000716 sameAs 2061000716 @default.
• W2061000716 citedByCount "120" @default.
• W2061000716 countsByYear W20610007162012 @default.
• W2061000716 countsByYear W20610007162013 @default.
• W2061000716 countsByYear W20610007162014 @default.
• W2061000716 countsByYear W20610007162017 @default.
• W2061000716 countsByYear W20610007162019 @default.
• W2061000716 crossrefType "journal-article" @default.
• W2061000716 hasAuthorship W2061000716A5003574683 @default.
• W2061000716 hasAuthorship W2061000716A5005594026 @default.
• W2061000716 hasAuthorship W2061000716A5010456669 @default.
• W2061000716 hasAuthorship W2061000716A5013939045 @default.
• W2061000716 hasAuthorship W2061000716A5019048597 @default.
• W2061000716 hasAuthorship W2061000716A5020907777 @default.
• W2061000716 hasAuthorship W2061000716A5021332351 @default.
• W2061000716 hasAuthorship W2061000716A5025166897 @default.
• W2061000716 hasAuthorship W2061000716A5029984844 @default.
• W2061000716 hasAuthorship W2061000716A5031856721 @default.
• W2061000716 hasAuthorship W2061000716A5033935778 @default.
• W2061000716 hasAuthorship W2061000716A5047187056 @default.
• W2061000716 hasAuthorship W2061000716A5067184222 @default.
• W2061000716 hasAuthorship W2061000716A5073667628 @default.
• W2061000716 hasAuthorship W2061000716A5075280681 @default.
• W2061000716 hasAuthorship W2061000716A5076077834 @default.
• W2061000716 hasAuthorship W2061000716A5077198246 @default.
• W2061000716 hasAuthorship W2061000716A5078557608 @default.
• W2061000716 hasAuthorship W2061000716A5084862920 @default.
• W2061000716 hasAuthorship W2061000716A5089395073 @default.
• W2061000716 hasConcept C126322002 @default.
• W2061000716 hasConcept C141071460 @default.
• W2061000716 hasConcept C2776694085 @default.
• W2061000716 hasConcept C2776755627 @default.
• W2061000716 hasConcept C2777063308 @default.
• W2061000716 hasConcept C2777938653 @default.
• W2061000716 hasConcept C2778461978 @default.
• W2061000716 hasConcept C2779263901 @default.
• W2061000716 hasConcept C2781413609 @default.
• W2061000716 hasConcept C29730261 @default.
• W2061000716 hasConcept C71924100 @default.
• W2061000716 hasConcept C90924648 @default.
• W2061000716 hasConceptScore W2061000716C126322002 @default.
• W2061000716 hasConceptScore W2061000716C141071460 @default.
• W2061000716 hasConceptScore W2061000716C2776694085 @default.
• W2061000716 hasConceptScore W2061000716C2776755627 @default.
• W2061000716 hasConceptScore W2061000716C2777063308 @default.
• W2061000716 hasConceptScore W2061000716C2777938653 @default.
• W2061000716 hasConceptScore W2061000716C2778461978 @default.
• W2061000716 hasConceptScore W2061000716C2779263901 @default.
• W2061000716 hasConceptScore W2061000716C2781413609 @default.
• W2061000716 hasConceptScore W2061000716C29730261 @default.
• W2061000716 hasConceptScore W2061000716C71924100 @default.
• W2061000716 hasConceptScore W2061000716C90924648 @default.
• W2061000716 hasIssue "2" @default.
• W2061000716 hasLocation W20610007161 @default.
• W2061000716 hasLocation W20610007162 @default.
• W2061000716 hasOpenAccess W2061000716 @default.
• W2061000716 hasPrimaryLocation W20610007161 @default.
• W2061000716 hasRelatedWork W1964100413 @default.
• W2061000716 hasRelatedWork W2023984538 @default.
• W2061000716 hasRelatedWork W2044556191 @default.

• next